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was achieved using medical records and/or phone calls and was censored at 2 years.
Descriptive analysis was performed on all variables. Univariate analysis and propensity
matched analysis were performed to determine differences between the 2 cohorts.
Results: E had more hypertension and a higher angiographic complexity than Y patients
as judged by SYNTAX scoring (E 22.4  14.2; Y 17.5  12.5, p  0.026). A higher
prevalence of smoking, obesity and family history of premature heart disease was seen in
Y patients. At 2 years follow up, Y vs. E patients had the following outcomes respectively:
TLF 27.7% and 25.5% (p0.711), TLR (24.8% vs. 21.4%, p0.518), cardiac death
(3.4% vs. 2.5%, p0.750) and definite and probable stent thrombosis (2.0% vs. 1.0%).
Propensity matched analysis showed a statistically similar TLF and TVF between the Y
and E cohorts respectively (31.3% vs. 21.9% (p0.317) and 46.2% vs. 32.3% (p0.150)
respectively). The EES had lower TLR than PES in the E (15.7% vs. 27.7%, p0.055)
but similar outcomes between the 2 stents were seen in the Y cohort.
Conclusion: In this cohort of patients receiving EES and PES, and when compared to
young patients ( 65 years), elderly patients ( 65 years) had more complex angiographic
disease but statistically similar outcomes at 2- year follow-up. EES appears to have lower
TLR in elderly patients than PES.
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Background: To evaluate the safety and effectiveness of the Elixir DESyneTM BD
Novolimus Eluting Coronary Stent System (CSS) with a bioabsorbable polymer com-
pared to the Endeavor Zotarolimus Eluting Coronary Stent System through the
assessment of clinical, angiographic, and IVUS endpoints.
Method: 149 patients were randomized 3:1, either to the Elixir DESyne BD Novolimus
Eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a sirolimus
metabolite, eluted via a bioabsorbable polylactide-based polymer, or to the Endeavor
Zotarolimus-eluting CSS loaded with 10mcg per mm of stent length of Zotarolimus
eluted via a durable phosphoryl choline polymer. All patients were analyzed for the
primary endpoint of in-stent late lumen loss (LLL) assessed by QCA at 6 months.
Moreover, all patients underwent evaluation for the secondary endpoints including the
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization; clinically-indicated Target Vessel Revascularization (TVR), and stent thrombosis
at 1, 6, 9, and 12 months and annually through 5 years. Lesions were also evaluated for
angiographic endpoints at 6 months including: in-segment LLL, percent diameter
stenosis, minimal lumen diameter post-procedure and at 6 months, and angiographic
binary restenosis (ABR) (50%). A subset of patients underwent intravascular ultrasound
(IVUS) evaluation including percent (%) neointimal obstruction at 6 months.
Results: The study met the primary endpoint demonstrating both non-inferiority and
superiority of the DESyne BD compared to the control (0.120.15 vs 0.670.47,
p0.001), additionally, in-stent ABR was significantly lower for DESyne BD (0% vs
7.9%, p0.003). Excellent clinical results at 6 months were demonstrated for both
devices. Clinical results through 12 months and additional angiographic and IVUS results
will be presented.
Conclusion: Clinical results through 12 months and complete angiographic and IVUS
results will be presented.
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Background: Chronic total occlusion (CTO) intervention is still challenging because of
the limited procedural success rate and higher recurrence. It is not clear whether the
peri-procedural myocardial infarction (P-MI) will significantly impact on angiographic
and clinical outcomes following CTO intervention.
Methods: A total of 131 consecutive pts underwent CTO intervention were divided into
P-MI (n12) and control group (n119). Six-month angiographic and twelve-month
clinical outcomes were compared between the two groups.
Results: The baseline clinical characteristics were balanced between the two groups
except more elderly (66.113.0 vs. 60.19.4 p0.034) in the P-MI group. There were
higher incidence of perforation (15.3% vs. 0.7%, p0.0005), dissection (46.1% vs.18.1%,
p0.018), any hematoma and acute renal failure in the P-MI group. Angiographic
outcomes at 6 months were not different between the two groups. However, the incidence
of total death, any myocardial infarction (MI) and target vessel revascularization
(TVR)-major adverse cardiac events (MACE) were higher in the P-MI group at 24
months (Table).
Conclusions: P-MI following CTO intervention was associated with higher 2-year
mortality, any MI and TVR-MACE. Careful procedure to minimize P-MI will be
warranted to get optimal CTO intervention outcomes.
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